Corso Research Newsletter

Trading is simply how we monetize our research.Not Financial Advisors.

[Corso Research Newsletter @corsoresearch]

@JowiPozoX

[Corso Research Newsletter @corsoresearch]

@JowiPozoX @ivanlezcano030

[Corso Research Newsletter @corsoresearch]

$usau paid promotion 🤨🤨🤨

[First Squawk @FirstSquawk]

Trump: We will head to Cuba after completing the mission in Iran

[Corso Research Newsletter @corsoresearch]

#cuba

[Corso Research Newsletter @corsoresearch]

#spy #qqq #stocks

[Corso Research Newsletter @corsoresearch]

Axios reports the Trump DOJ antitrust division opened a criminal probe into the beef industry over alleged collusion and manipulation of cattle pricing benchmarks in rancher contracts.
#StockMarketNews #spy #qqq

[Corso Research Newsletter @corsoresearch]

#oscr #spy #qqq #stocks

[Corso Research Newsletter @corsoresearch]

IRÁN AND TRUMP THIS WEEKEND #trump #iran #spy

[Corso Research Newsletter @corsoresearch]

#cuba

[First Squawk @FirstSquawk]

TRUMP SAYS WE MAY STOP BY CUBA AFTER WE'RE FINISHED WITH IRAN

[Corso Research Newsletter @corsoresearch]

@theepicmap What about Cuba 🇨🇺? Thas the first place 🥇

[Corso Research Newsletter @corsoresearch]

@stats_feed #Cuba have 90%

[Corso Research Newsletter @corsoresearch]

@Mr_Derivatives Fallow the Smart money…except this time !!!!!! Split reversal tomorrow

[Corso Research Newsletter @corsoresearch]

When messaging and insider behavior diverge this sharply, it often suggests material information is being withheld or selectively framed.

[Corso Research Newsletter @corsoresearch]

$TVTX released a corporate update today filled with ambiguous language and carefully framed optimism — while avoiding meaningful clarity on its FDA situation.

Prior negative FDA feedback is not addressed in detail, and key regulatory risks appear downplayed.

[Corso Research Newsletter @corsoresearch]

At the same time, multiple insiders have been selling shares for months, with zero insider buying reported ahead of a major regulatory decision.

[Corso Research Newsletter @corsoresearch]

$tvtx Rejected

[Will Meade @thechartdr]

Insane volume in $TIGR weekly $9 and $10 calls this morning

[PDUFA Pulse @PDUFA_Pulse]

🧪 Pre-Mortem Desk preview (from Fri’s issue):
📅 $TVTX FILSPARI (FSGS full approval) — Jan 13 | PoA 70 (High)
The hinge: proteinuria vs eGFR slope framing + label language around acute dip / total-slope.
This is a tight corridor.

[Kris Siemionow, MD, PhD @siemionowkris]

Here are three major biotech catalysts this week that could drive significant stock movement: Atara Biotherapeutics $ATRA), Travere Therapeutics $TVTX), and **Fortress Biotech $FBIO) — all with PDUFA dates on the FDA calendar!

Today (Jan 10, yes a Saturday): $ATRA's tabelecleucel (tab-cel) PDUFA for EBV+ PTLD — potential first U.S. approval for this rare, aggressive condition in post-transplant patients. Priority review after resubmission; if greenlit, $ATRA gets a $40M milestone from Pierre Fabre! High-stakes cell therapy play.

Next up:
- Jan 13: $TVTX's FILSPARI (sparsentan) sNDA PDUFA for FSGS — could make it the **first & only** FDA-approved treatment for this rare kidney disease leading to failure. Building on IgAN success, huge expansion potential.

- Jan 14: $FBIO's CUTX-101 (copper histidinate) NDA PDUFA for Menkes disease — priority rare pediatric therapy, Class 1 resubmission after addressing manufacturing. First approval here would be transformative for this ultra-rare, fatal condition.

Busy week ahead in rare disease & oncology biotech — approvals could spark big moves, delays the opposite. $ATRA $TVTX $FBIO #Biotech #PDUFA #FDA